SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 10549
FORM 10KSB/A
AMENDMENT TO APPLICATION OR REPORT
Filed pursuant to Section 13 or 15(d) of
THE SECURITIES AND EXCHANGE ACT OF 1934
IGENE BIOTECHNOLOGY, INC.
(Exact name of registrant as specified in charter)
AMENDMENT NO. 1
The undersigned registrant hereby amends the following
items, financial statements, exhibits or other portions of its
1995 report on Form 10KSB as set forth in the pages attached
hereto:
1) FILER INFORMATION; PAGE 1 (Final line referencing
Exhibit Index location - Previously omitted)
2) EXHIBIT INDEX; PAGE 38
3) FINANCIAL DATA SCHEDULE; EXHIBIT 27; PAGE 73
Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this Amendment to be
signed on its behalf by the undersigned, thereunto duly
authorized.
IGENE BIOTECHNOLOGY, INC.
Date: May 30, 1996 By:
Stephen F. Hiu
President, Treasurer, and
Secretary
<PAGE>
10KSB/A
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 10549
(Mark One)
[x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 [FEE REQUIRED]
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 [NO FEE REQUIRED]
For the transition period from to
Commission file number 0-15888
IGENE Biotechnology, Inc.
(Exact name of small business issuer in is charter)
Maryland 52-1230461
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)
9110 Red Branch Road
Columbia, Maryland 21045
(Address of principal executive offices (Zip Code)
Issuer's telephone number, including area code: (410) 997-2599
Securities registered pursuant to Section 12(b) of the Exchange
Act:
Title of each class Name of each exchange on which registered
None None
Securities registered pursuant to Section 12(g) of the Exchange
Act:
Common Stock (par value $.01 per share)
(Title of each class)
Check whether the issuer (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Exchange Act during the past
12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
YES X NO
Check if there is no disclosure of delinquent filers in response
to Item 405 of Regulation S-B contained in this form, and no
disclosure will be contained, to the bet of registrant's
knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. [ ]
The issuer's net revenues for its most recent fiscal year were
$274,978.
As of March 1, 1996, there were 18,572,805 shares of the issuer's
Common Stock and 225,342 shares of the issuer's 8% Cumulative
Convertible Preferred Stock, Series A, outstanding. The
aggregate market value of the Common Stock and Preferred Stock
held by non-affiliates was $3,699,682, based on the last bid
quotation prices of the Common Stock as reported by the National
Association of Securities Dealers pink sheets on such date and,
with respect to the Preferred Stock for which no quotations were
available, based on the conversion rate applicable to the
Preferred Stock and the last bid price of the Common Stock as
reported above. (The officers and directors of the issuer are
considered affiliates only for purposes of this calculation.)
Exhibit Index can be found on page 38.
Page 1
EXHIBIT INDEX
Page
10.11 Letter Agreement executed May 11, 1995
between Archer Daniels Midland and IGENE
Biotechnology, Inc., along with November 11,
1995 Amendment .................................. 39
10.13 Agreement of Lease effected December 15, 1995
between Columbia Warehouse Limited Partnership
and IGENE Biotechnology, Inc. ................... 50
27 Financial Data Schedule for fiscal year ended
December 31, 1995 ............................... 73
Page 38
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the Registrant has duly caused
this Report to be signed on its behalf by the undersigned,
thereunto duly authorized, in Columbia, Howard County, State of
Maryland on May 30, 1996.
IGENE Biotechnology, Inc.
Date: May 30, 1996 By: /s/ Stephen F. Hiu,
President
Pursuant to the requirements of the Securities Act of 1933, this
report is to be signed below by the following persons in the
capacities indicated.
Signature Title Date
/s/ Joseph C. Abeles Director May 30, 1996
(Joseph C. Abeles)
/s/ John A. Cenerazzo Director May 30, 1996
(John A. Cenerazzo)
/s/ Stephen F. Hiu Director, May 30, 1996
(Stephen F. Hiu) Secretary, and Treasurer
Chief Financial Officer,
Chief Accounting Officer
/s/ Thomas L. Kempner Vice Chairman May 30, 1996
(Thomas L. Kempner) of the Board
/s/ Michael G. Kimelman Chairman of May 30, 1996
(Michael G. Kimelman) of the Board of Directors
/s/ Sidney R. Knafel Director May 30, 1996
(Sidney R. Knafel)
/s/ Patrick F. Monahan Director May 30, 1996
(Patrick F. Monahan)
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1995
<PERIOD-START> JAN-31-1995
<PERIOD-END> DEC-31-1995
<CASH> 8,326
<SECURITIES> 0
<RECEIVABLES> 55,809
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 64,135
<PP&E> 29,520
<DEPRECIATION> 0
<TOTAL-ASSETS> 104,255
<CURRENT-LIABILITIES> 401,127
<BONDS> 1,500,000
<COMMON> 185,728
484,643
1,875
<OTHER-SE> (2,469,118)
<TOTAL-LIABILITY-AND-EQUITY> 104,255
<SALES> 25,563
<TOTAL-REVENUES> 274,978
<CGS> 16,878
<TOTAL-COSTS> 16,878
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 130,524
<INCOME-PRETAX> (503,156)
<INCOME-TAX> 0
<INCOME-CONTINUING> (503,156)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (503,156)
<EPS-PRIMARY> (.04)
<EPS-DILUTED> (.04)
</TABLE>
